key: cord-1047890-mlop701o
authors: Asem, N.; Massoud, H. H.; Serag, E.; Hassany, M.; ElAssal, G.; Abdelbary, A.; Mohsen, M.; Zaky, S.; Amin, W.; Kamal, E.; Ibrahem, H.; Mohsen, A. S.; Aly, M. A.; Elgendy, N.; Elbadry, M.; Ahmed, S. H.; Shenouda, N. N.; Fathy, M. A.; Zaid, H.
title: Clinical efficacy of Early Administration of Convalescent Plasma among COVID-19 Cases in Egypt
date: 2021-04-04
journal: nan
DOI: 10.1101/2021.03.30.21254031
sha: 4b3a361596dc29f1dce5a517a946d792ae0dd58c
doc_id: 1047890
cord_uid: mlop701o

Abstract Importance: Early and effective treatment of COVID-19 is vital for control of SARS-CoV-2 infection Objectives: The primary objective of the study was to assess the degree of clinical improvement in severe and critically ill COVID-19 patients, treated early with early CPT. Designs: An interventional, single-arm, non-randomized clinical trial conducted in Egypt from April 15 to July 21, 2020. Settings: This was a multi-centre study conducted in 3 hospitals in Egypt. Participants: a total of 94 COVID-19 laboratory-confirmed patients using qRT-PCR were enrolled in the study. Intervention: All patients were administered with two plasma units (each unit is 200cc). The volume of donated plasma was 800cc. Main Outcome and Measures: Primary measure was the degree of clinical improvement among the COVID-19 patients who received CPT within seven days Results: A total of 94 patients were enrolled who received CPT either within seven days or after seven days of hospitalization. 82 were severely ill, 12 were critically ill. The average age remained 58 years (SD 15.1 years). Male were 69% and 49% patients got cured while 51% died with CFR 51%. 75% deaths were above 45years of age. The symptoms were dyspnoea (55%), fever (52%), cough (46%), and loss of taste and smell (21%), and cyanosis (15%). The most common co-morbidities among the <40 years remained Diabetes Mellitus (21%) and Asthma (14%). Among 40-60 years Hypertension (56%), Diabetes Mellitus (39%) and among >60 years age group Hypertension (57%) and Chronic Heart Disease (24%) were reported. CPT within seven days remained significant as compared with the CPT after seven days with the number of days to cure (p=0.007) and ICU stay (P=0.008) among severely ill cured cases. Conclusion and Relevance: Among patients with COVID-19 and severe or critical illness, the use of CPT along with routine standard therapy resulted in a statistically significant improvement when administered within seven days of hospital admission. However, plasma transfusion, irrespective of days to transfusion may not help treat critically ill patients. The overall mean time to cure in severely ill patients was 15 days if CPT provided within seven days with 65% cure rate. Trial Registration: Clinical Intervention identifier: MOHP_COVID-19_Ver1.1

The rapid worldwide spread of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS- or COVID-19 pandemic from its epicentre; Wuhan has led to an epidemiological breakdown. The virus has caused an array of symptoms predominantly upper respiratory tract infections, and a significant increase in hospitalizations for pneumonia, deaths with multi-organ failure while triggering an economic downturn upending the global economy. A total of51,28 million cases have been reported across 213 countries with 36,34million recovered, and 1.28 million deaths 1 .

Egypt reported its first COVID-19 case on Feb 14, 2020 2 Passive immunization therapies treating infectious diseases date back to the 1920s', providing instantly available therapeutic strategies for conferring direct immunity to susceptible individuals. Blood from an individual who has recovered from the disease is drawn and screened for high titters neutralizing All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 4, 2021. ; https://doi.org/10.1101/2021.03.30.21254031 doi: medRxiv preprint antibodies, convalescent plasma containing these neutralizing antibodies is then administered in individuals with the infectious disease. Antibodies bind to the pathogen and directly neutralize its effectivity via antibody-mediated pathways, such as complement activation, antibody-dependent cellular cytotoxicity, and/or phagocytosis. Non-neutralizing antibodies that bind to the pathogen contribute to reducing symptoms and mortality, as they do not interfere in the pathogen's ability to replicate within in-vitro symptoms 5 .

The use of CPT against coronaviruses was first tested during SARS1 outbreak in 2003. One of the largest SARS1 studies involved a total of 80 patients in Hong Kong. Results showed that patients treated before 14 days, had improved outcomes 6 Clinical trial data from previous studies suggest that using similar CPT protocols could be beneficial in patients infected with SARS-CoV-2. However, there is a lack of robust evidence, generated from the data of large clinical trials that confirm the efficacy of this treatment modality.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The objective of the study was to assess the clinical efficacy of early start of convalescent plasma amongSARS-CoV-2patients as well as to observe intensive care unit (ICU) characteristics and fatality among severe and critically ill patients diagnosed with SARS-CoV-2.

An interventional, single-arm, non-randomized, multi-centre clinical trial was conducted from 15 th April to 21 st July 2020 in Egypt. The study was approved by the Ministry of Health and Population Ethics Committees (MOHP-EC) and was registered in Egypt no. MOHP_COVID-19_Ver1.1.

Initially, 30 patients were enrolled and later extended where a total of 102 patients tested positive, using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) in Central laboratories and upon their admission to the hospital either with severe or life-threatening disease they were included in the study. A total of 94 patients were finally enrolled in the study after exclusion of patients who did not meet the criteria and written informed consent was taken. All patients included in the study have laboratory proven as SARS-CoV-2& had bilateral infiltrates>50% and categorized as severely ill when having hypoxia and critically ill in case of mechanical ventilation use. Patients had received a combination of antiviral agents, antibiotics, and steroids according to the SARS-CoV-2 treatment protocol by Ministry of Health. All patients received 2 convalescent plasma units (Each unit is 200cc) (Figure-1 ).

Symptomatic patients were tested for SARS-CoV-2using nasopharyngeal or oropharyngeal swabs through-PCR -a validated assay protocol approved by the World Health Organization (WHO).

Donors between the ages 18-60, with a clinical and laboratory-confirmed recovered diagnosis of SARS-CoV-2were selected. Selected donors had complete resolution of symptoms at least 14 days before donation and negative results for SARS-CoV-2 either from one or more nasopharyngeal swab specimens or by a molecular diagnostic test from the blood. Neutralization antibodies are measured by Microneutralization technique 8 . Donors with a measurement of neutralizing antibody titers more than 1:320 (accepted till 1:80) along with anFDA approved defined serum SARS-CoV-2 specific chemiluminescence antibody titer higher than 1:320 were included. The investigators tested donor units using the Ortho VITROS SARS-CoV-2 total antibodies as per approved FDA guidelines 9 . Units containing anti-SARS-CoV-2 antibodies but not qualified as high titer by the Ortho VITROS SARS-CoV-2 total antibody are considered low titer units.

The volume of donated plasma was 800cc and all donors' samples were routinely virology screened for HBsAg, HCV Ab, HIV Ag/Ab, Syphilis Ab by using Chemiluminescence technique and were also screened by NAT for HBV DNA, HCV RNA& HIV ½ RNA. All donors provided consent and container labels of convalescent plasma units included the following statement, "Caution: New Drug--Limited to investigational use." All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Descriptive and inferential analyses were performed. For the quantitative variables; frequencies, averages and standard deviations were calculated. For the timing of the convalescent plasma administered variable coding was done as 1 for CP administration within 7 days of hospitalization and 2 for CP administration after 7 days of hospital administration. Independent t test was applied for comparing the mean duration to cure and ICU stay among the categories of the timing of CP administration. Level of significant was selected as 0.05 and significance values (p) compared. N-1 chi-square test was also applied. IBM® SPSS® was used for analysis.

A total of 94 COVID-19 patients including 82 (87%) severely ill and 12 (13%) critically ill were enrolled in the current study and administered two units of convalescent plasma transfusions, within 24 hours, either within 7 days or after 7 days of hospitalization. Patients were divided into three groups; less than 40 years, 40-60 years, and greater than 60 years of age. Each group included 13 (16%), 30 (37%), and 39 (47%) severely ill patients while 1 (8%), 4 (33%), and 7 (58%) critically ill patients, respectively.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 4, 2021. ; https://doi.org/10.1101/2021.03.30.21254031 doi: medRxiv preprint

The average age remained 58 years (±SD 15.1 years) Among the 94 enrolled patients while the average age among <40 years, 40-60 years and >60 years remained 32(±SD 4), 51 (±SD 6) and 71 (±SD 6).

Among the total patients 65 (69%) were male. A total of 46 (49%) patients got cured while 48 (51%) died. The symptoms were dyspnoea (55%), fever (52%), cough (46%), and loss of taste and smell (21%), and cyanosis (15%). The most common co-morbidities among the <40 years remained Diabetes Mellitus (21%) and Asthma (14%). Among 40-60 years age group Hypertension (56%), Diabetes Mellitus (39%), and among >60 years age group Hypertension (57%), Chronic Heart Disease [(24%), and Chronic Kidney Disease were the most frequently reported co-morbidities.

Among the total 94 cases 82 (87%) were severely ill cases out of them 46 (56%) cured while 36 (44%) died. A total of 52 (63%) received CPT within seven days of hospital admission while 30 (37%) cases received CPT after seven days. The average days to cure remained 15 days (±SD7.3) among those who received CPT within seven days while the average days to cure remained 23 (±SD 9.4) who received CPT after seven days and difference remained statistically significant p=0.007.

Among the severely ill cases the cure rate among the cases who received CPT within seven days was 65% while among those who received CPT after seven days remained 40%. The difference remained 25% which is statistically significant (p=0.016).

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Among the total 82 severely ill cases46 were categorized as severely illcured. The average age of severely-cured patients remained 57.3 years (±SD 15 Years). Male were 33 (72%) and female were 13 (28%). Clinical sign and symptoms remained as dyspnoea 44 (96%), cough 38 (82%), fever 34 (74%), cyanosis 10 (21%) and loss of taste and smell 7 (15%). Reported co-morbidities remained as hypertension 23(50%), Diabetic 13(28%), heart disease 6 (13%), Asthma 5 (11%), COPD 4 (9%), Kidney disease 3 (7%) and Chronic liver disease2 (4%).

Out of the total 45 (97%) patients treated with antibiotics and steroids, while 36, (78%) patients were treated with combination of Hydroxychloroquine and 4 (9%) patients were treated with Oseltamivir and Lopinavir/Ritonavir. The mean lowest SPO2, S/F ratio, PAO2, and P/F ratio reported across all age groups as76. 15, 190 .37, 49.28, and 143.5 respectively. (Table-1) Among the 46 severely-ill cured cases 34 (74%) received plasma within 7 days while 12 (40%) cured cases received plasma after seven days. The average days to cure the cases who received plasma within seven days remained 15 days (± SD 7 days) while the average days to cure who received plasma after seven days remained 23 (±SD 9). The mean difference remained significantly different among both groups (P=0.007). Similarly, the cases who received plasma within seven days the average ICU stay remained 6 days (±SD 4 days) while the cases who received plasma after seven days the average ICU All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 4, 2021. ; https://doi.org/10.1101/2021.03.30.21254031 doi: medRxiv preprint stay was 11 days (±SD 7 days). The difference in the average ICU stay remained significant (p=0.008) ( Table 2) .

Among the total 82 severely ill cases of 36 s were categorized as severely ill -died, patients across all Lopinavir/Ritonavir was given to 11% (n=4) of the subjects. The mean lowest SPO2, S/F ratio, PAO2, and P/F ratio reported across all age groups were 68.96, 155, 56.67, and 129.8, respectively (Table 3) .

At admission, 32 of the 36 patients reported to the hospital with dyspnoea, which increased progressively before transfusion.

Among the severely ill died cases 18 (50%) received plasma within 7 days while 18 (50%) received plasma after seven days. The cases who received plasma within seven days the average ICU stay remained 7 days (±SD 5 days) while the cases who received plasma after seven days the average ICU stay was 4 days (±SD 3 days). The difference remained significant (p=0.04) ( Table 4 ). All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Out of the total 12 patients were categorized as critically ill -died, patients across all age groups. The average age remained 57 years (±SD 12 Years). Male were 10 (83%) and female were 2 (17 %). Clinical sign and symptoms remained as dyspnoea 12 (100%), cough& Fever9 (75%), cyanosis 6 (50 %) and loss of taste and smell 2 (17 %). Reported co morbidities remained as hypertension 6 (50 %), Diabetic 4 (33 %), heart disease, Kidney diseases and Asthma remained2 (17%).

All the critically ill died cases were treated with steroid while 9 (75%) cases were treated with antibiotics, a combination of Hydroxychloroquine was given to 10 (83%) and Lopinavir/Ritonavir was provided to 1 (8%) ( Table 5 ).

The mean lowest SPO2, PAO2, and P/F ratio reported across all age groups were 71.75, 51.13, and 90.33, respectively. It was observed that there was no significant difference between patients administered with plasma within or after 7 days of administration.

Out of the total 94 COVID-19 Cases 46 cases got cured while 48 cases died (CFR 51%). Among the total died cases the average age remained 58 (±SD 15). The most frequent age among died cases was 73 (Mode), 25% deaths were under 45 years of age(First quartile), 50% deaths were up to 61 years of age (Second Quartile), 75% deaths were up to 70 years of age (Third Quartile) and 25% deaths were All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 4, 2021. ; https://doi.org/10.1101/2021.03.30.21254031 doi: medRxiv preprint above the 70 years of age. 67% male were died and 33% female died. Respiratory complications were more reported among the dead cases.

The current study has shown that early administration of convalescent plasma in COVID-19 patients remained a critical measure for its clinical efficacy in severely ill patients. However, plasma transfusion, irrespective of days to transfusion may not be helpful in treating critically ill patients.

In history, several studies 10,11, 12 have reported treatment with convalescent plasma transfusions for viral infections. Similar results were provided by a study published in china on April 2020, a total of 10 severely ill COVID-19 patients were enrolled in the study and single dose of 200ml plasma was administered to each of the subject and there was significant improvement in the clinical symptoms 13 Some other published studies also provided the plasma transfusion should be done during the early phase of the diseases and will be more beneficial 14, 15 . China provided the usefulness of plasma transfusion among the critically ill COVID-19 cases. In this study 5 critically ill cases were enrolled and received transfusion body temperature normalized within 3 days in 4 of 5 patients, the SOFA score decreased, and PAO2/FIO2 increased within 12 days (range, 172-276 before and 284-366 after). Viral loads also decreased and became negative within 12 days after the transfusion. 16 Similar results were observed in influenza A (H1N1) patients, where patients who received plasma transfusions (n=20) had significantly fewer deaths when compared to controls (n=73) deaths (20% vs. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 4, 2021. ; https://doi.org/10.1101/2021.03.30.21254031 doi: medRxiv preprint 54.8%; P=.01). 17 These positive effects of plasma transfusions in viral infections can be attributed to the humoral immunity established in recovered patients containing a large quantity of neutralizing antibodies capable of neutralizing SARS-CoV-2 and eradicating the pathogen from blood circulation and pulmonary tissues. In this multi-centre non-randomized study, 94 patients (82 severely ill and 12 critically ill) with SARS-CoV-2 were treated with convalescent plasma. As assessed by days to transfusion (before and after 7 days) from date of admission, clinical symptoms such as dyspnoea, cyanosis, fever, and cough improved within days of transfusion of plasma. This response time may have impact on pandemic economy as shorter duration of hospital stay leads to reduced cost. A study was published to examine the economic consequences of hospital admissions. And it is evident that with long stay there is a significant implication of the economics and increase of the out of pocket 18 .

The current study provided that clinical respiratory parameters also improved in all cured patients. The results, therefore, support the initial hypothesis stating that CPT at an early stage may be effective in treating SARS-CoV-2. Similar results were provided by a study published during June 2020 in China.

This study comprehensively evaluated the effectiveness, safety, and indications of convalescent plasma transfusion (CPT) therapy for severe or critical COVID-19 patients. It is provided that 70% of the cases with severe respiratory symptoms showed improvement and removed oxygen supports within 7 days after CPT 19 .

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Our study also reports the deaths of critically ill patients who were placed on invasive mechanical ventilation before plasma transfusions. All 12 patients in this group died& they had respiratory system complications predominantly including pneumonia. All patients, irrespective of days to plasma transfusions had prolonged ICU stay similar to other studies. Similar results are evident form a metaanalysis published during May 2020 and provided that among the fatal cases the prevalence of respiratory co morbidities is higher [10.89% (95%CI: 7.57%, 15.43%)] as compared to the total cases (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 4, 2021. ; https://doi.org/10.1101/2021.03.30.21254031 doi: medRxiv preprint (fever, cough, shortness of breath, and chest pain) in all 10 patients within 1 to 3 days of plasma transfusions. 16 .

Due to the clinical features of included patients; the investigators could not conduct a randomized controlled trial. However, we understand that a controlled study may further help in establishing the dynamics of the viremia of SARS-CoV-2 while capturing the optimal transfusion time point.

Additionally, all patients were also treated with multiple pharmaceutical agents including antibiotics, antivirals, and steroids requiring robust comparative analyses to clearly establish the effect of each treatment modality individually and collectively as well.

This non-randomized clinical trial demonstrates the clinical efficacy of early convalescent plasma in treating SARS-CoV-2 infected patients. The study results indicate that cure rates are significantly better when plasma is administered within the first seven days of hospital admission for severe cases. The (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 4, 2021. ; 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 4, 2021. ;

• AKD n(%) (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 4, 2021. ; https://doi.org/10.1101/2021.03.30.21254031 doi: medRxiv preprint

COVID-19 Dashboard by the Center for Systems Science and Engineering

Mohamed El Kassas. COVID-19 in Egypt: Uncovered figures or a different situation

Estimation of COVID-19 burden in Egypt

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review

History of Passive Antibody Administration for Prevention and Treatment of Infectious Diseases

Use of convalescent plasma therapy in SARS patients in Hong Kong

Convalescent plasma: new evidence for an old therapeutic tool

Krammer2 An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening

COVID-19 convalescent plasmademergency INDs. Available at: FDA; 2020

Deployment of convalescent plasma for the prevention and treatment of COVID-19. Available at

Xinxin Zhang, and View ORCID ProfileXiaoming Yang. Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Use of Convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks. Interim Guidance Natl Health Authorities

Use of convalescent plasma in hospitalized patients with Covid-19dcase series

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection

The Economic Consequences of Hospital Admissions

LingxiangWu.Improved Clinical Symptoms and Mortality on Severe/Critical COVID-19 Patients Utilizing Convalescent Plasma Transfusion

COVID-19 and comorbidities: a systematic review and meta-analysis

SARS-CoV-2 viral load and the severity of COVID-19

Viral load and sequence analysis reveal the symptom severity, diversity, and transmission clusters of rhinovirus infections

Convalescent plasma for COVID-19: a randomized clinical trial

• Lowest SPO2 71.7 (15) 

• AKD n(%) 4 (33) 0(0) 1(25) 3 (43) Pharmacological Treatment• Antibiotics 9 (75) 1 (100) 2 (50) 6 (86)• Oseltamivir 0(0) -0 (0) 0 (0)• Hydroxychloroquine 10 (83) 1(100) 3 (75) 6 (86)• Lopinavir/Ritonavir 1 (8) -1(25 ) 0 (0)• Steroids 12(100) 1 (100) 4 (100) 7 (100)